AspenBio falls on AppyScore data

AspenBio Pharma Inc. (NASDAQ:APPY) fell $0.28 (29%) to $0.69 on Tuesday after announcing it will not submit a new 510(k) application to FDA for its AppyScore ELISA-based screen/triage blood test for acute appendicitis. The company said data from a pivotal trial in 859 patients suspected of having the disease showed that the test led to an increased number of false positives. ...